Type 2 diabetes

VERTIS-CV trial delivers on heart failure with ertugliflozin

Ertugliflozin in addition to standard of care for patients with type 2 diabetes and atherosclerotic disease has been shown to reduce the risk of hospitalisation for heart failure (HHF) by 30% compared to placebo. The eValuation of ERTugliflozin EffIcacy and Safety CardioVascular Outcomes Trial (VERTIS-CV), presented at the virtual ADA 2020 Scientific Sessions, included data ...

Already a member?

Login to keep reading.

© 2021 the limbic